http://purl.org/np/RA_YLsU-_9ReKinT_QyJOHbLAlnnvrAt6dPA37DgUQxRc#Head
http://purl.org/np/RA_YLsU-_9ReKinT_QyJOHbLAlnnvrAt6dPA37DgUQxRc
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RA_YLsU-_9ReKinT_QyJOHbLAlnnvrAt6dPA37DgUQxRc#assertion
http://purl.org/np/RA_YLsU-_9ReKinT_QyJOHbLAlnnvrAt6dPA37DgUQxRc
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RA_YLsU-_9ReKinT_QyJOHbLAlnnvrAt6dPA37DgUQxRc#provenance
http://purl.org/np/RA_YLsU-_9ReKinT_QyJOHbLAlnnvrAt6dPA37DgUQxRc
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RA_YLsU-_9ReKinT_QyJOHbLAlnnvrAt6dPA37DgUQxRc#pubinfo
http://purl.org/np/RA_YLsU-_9ReKinT_QyJOHbLAlnnvrAt6dPA37DgUQxRc
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RA_YLsU-_9ReKinT_QyJOHbLAlnnvrAt6dPA37DgUQxRc#assertion
http://purl.obolibrary.org/obo/DOID_2449
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RA_YLsU-_9ReKinT_QyJOHbLAlnnvrAt6dPA37DgUQxRc#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_2449
http://purl.org/np/RA_YLsU-_9ReKinT_QyJOHbLAlnnvrAt6dPA37DgUQxRc#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RA_YLsU-_9ReKinT_QyJOHbLAlnnvrAt6dPA37DgUQxRc#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB00104
http://purl.org/np/RA_YLsU-_9ReKinT_QyJOHbLAlnnvrAt6dPA37DgUQxRc#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RA_YLsU-_9ReKinT_QyJOHbLAlnnvrAt6dPA37DgUQxRc#association
http://www.w3.org/2000/01/rdf-schema#label
acromegaly octreotide acetate injection is indicated to reduce blood levels of growth hormone and igf i somatomedin c in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection pituitary irradiation and bromocriptine mesylate at maximally tolerated doses the goal is to achieve normalization of growth hormone and igf i somatomedin c levels see dosage and administration improvement in clinical signs and symptoms or reduction in tumor size or rate of growth were not shown in clinical trials performed with octreotide acetate injection these trials were not optimally designed to detect such effects carcinoid tumors octreotide acetate injection is indicated for the symptomatic treatment of patients with metastatic carcinoid tumors where it suppresses or inhibits the severe diarrhea and flushing episodes associated with the disease octreotide acetate injection studies were not designed to show an effect on the size rate of growth or development of metastases vasoactive intestinal peptide tumors vipomas octreotide acetate injection is indicated for the treatment of the profuse watery diarrhea associated with vip secreting tumors octreotide acetate injection studies were not designed to show an effect on the size rate of growth or development of metastases
http://purl.org/np/RA_YLsU-_9ReKinT_QyJOHbLAlnnvrAt6dPA37DgUQxRc#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RA_YLsU-_9ReKinT_QyJOHbLAlnnvrAt6dPA37DgUQxRc#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RA_YLsU-_9ReKinT_QyJOHbLAlnnvrAt6dPA37DgUQxRc#association
https://w3id.org/biolink/vocab/relation
https://w3id.org/um/neurodkg/SymptomaticReliefIndication
https://identifiers.org/drugbank:DB00104
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RA_YLsU-_9ReKinT_QyJOHbLAlnnvrAt6dPA37DgUQxRc#provenance
http://purl.org/np/RA_YLsU-_9ReKinT_QyJOHbLAlnnvrAt6dPA37DgUQxRc#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RA_YLsU-_9ReKinT_QyJOHbLAlnnvrAt6dPA37DgUQxRc#pubinfo
http://purl.org/np/RA_YLsU-_9ReKinT_QyJOHbLAlnnvrAt6dPA37DgUQxRc#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RA_YLsU-_9ReKinT_QyJOHbLAlnnvrAt6dPA37DgUQxRc#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RA_YLsU-_9ReKinT_QyJOHbLAlnnvrAt6dPA37DgUQxRc#sig
http://purl.org/nanopub/x/hasSignature
Qw/dxPFErxuvhc33KVNLgIUvGYXGpxkNVXngA2pZmdnOB+4kts/xgB/xc1dkiqId+3JvoqzIBoGhSroA7lnAjFMqwPN0mDwETVnZifAA8ARoujC/MLONmKJs0PVOaUjCUmQlbgI3QbZyUscNHw9OEkz25tVfG7zhz/3y2Qidd3s=
http://purl.org/np/RA_YLsU-_9ReKinT_QyJOHbLAlnnvrAt6dPA37DgUQxRc#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RA_YLsU-_9ReKinT_QyJOHbLAlnnvrAt6dPA37DgUQxRc
http://purl.org/np/RA_YLsU-_9ReKinT_QyJOHbLAlnnvrAt6dPA37DgUQxRc
http://purl.org/dc/terms/created
2021-06-30T09:26:54.277+02:00
http://purl.org/np/RA_YLsU-_9ReKinT_QyJOHbLAlnnvrAt6dPA37DgUQxRc
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RA_YLsU-_9ReKinT_QyJOHbLAlnnvrAt6dPA37DgUQxRc
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RA_YLsU-_9ReKinT_QyJOHbLAlnnvrAt6dPA37DgUQxRc
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RA_YLsU-_9ReKinT_QyJOHbLAlnnvrAt6dPA37DgUQxRc
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs